GLP-1 receptor agonists (GLP1-RAs) show a modest reduction in HF hospitalization across CV outcome trials [44,109,110] and add a substrate-directed effect: EAT expresses GLP-1/GLP-2 receptors [111], and clinical studies report reductions in EAT thickness with liraglutide and dulaglutide, along with improved diastolic function with liraglutide versus placebo [112,113]. This evidence concerns the gene GLP1R and hydrops fetalis.